evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,822 questions · 1,891 findings · 321 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 279 · 14.8%GRADE not reported 46 · 2.4%Very low 524 · 27.7%Low 571 · 30.2%Moderate 330 · 17.5%High 141 · 7.5%

Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy

Metformin · people at increased risk for developing type 2 diabetes
2 findings from 1 review

Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy

Acarbose · people at increased risk for developing type 2 diabetes
2 findings from 1 review

Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy

Repaglinide · people at increased risk for developing type 2 diabetes
2 findings from 1 review

Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy

Metformin Diagnostic criteria: 2 studies applied the WHO 1999 criteria for 'prediabetes' (FPG > 6.1 mmol/L and < 7.0 mmol/L and/or a 2‐h glucose < 11.1 mmol/L after a 75 g OGTT; Chen 2007a; Zeng 2013) · people at increased risk for developing type 2 diabetes

Summary of findings: pioglitazone monotherapy showed no clear difference in metformin Diagnostic criteria: 2 studies applied the WHO 1999… compared with another pharmacological glucose‐lowering monotherapy (low certainty).

1 finding from 1 review

Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy

Acarbose Diagnostic criteria: 1 study applied the WHO 1999 criteria for prediabetes (FPG > 6.1 mmol/L and < 7.0 mmol/L and/or a 2‐h glucose < 11.1 mmol/L after a 75 g OGTT; Chen 2007a) · people at increased risk for developing type 2 diabetes
1 finding from 1 review

Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy

Repaglinide Diagnostic criteria: 1 study applied the ADA 2010 criteria (FPG ≥ 5.6 mmol/L and < 6.9 mmol/L and 2‐h glucose ≥ 7.8 mmol/L or < 11.0 mmol/L after a 75 g OGTT; Zhang 2007) · people at increased risk for developing type 2 diabetes
1 finding from 1 review

Bakri balloon tamponade vs haemostatic square suturing to the lower segment of the uterus (intrauterine tamponade versus another mechanical/surgical method)

Serious maternal morbidity (renal or respiratory failure, cardiac arrest or multiple organ failure) · women with complete placenta praevia and intractable bleeding following caesarean section
1 finding from 1 review

Bakri balloon tamponade vs haemostatic square suturing to the lower segment of the uterus (intrauterine tamponade versus another mechanical/surgical method)

Number of women with total blood loss 1000 mL or more after randomisation · women with complete placenta praevia and intractable bleeding following caesarean section

The review found no eligible studies for this question.

1 finding from 1 review

Bakri balloon tamponade vs haemostatic square suturing to the lower segment of the uterus (intrauterine tamponade versus another mechanical/surgical method)

Blood transfusion (red cell or whole blood) · women with complete placenta praevia and intractable bleeding following caesarean section

It is very uncertain whether bakri balloon tamponade changes blood transfusion (red cell or whole blood) compared with haemostatic square suturing to the lower segment of the uterus… (very low certainty).

1 finding from 1 review

Bakri balloon tamponade vs haemostatic square suturing to the lower segment of the uterus (intrauterine tamponade versus another mechanical/surgical method)

Side effects of the intervention (e.g. trauma, necrosis) · women with complete placenta praevia and intractable bleeding following caesarean section
1 finding from 1 review